Khadija Mbbs Alam
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Khadija Mbbs Alam has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
- Abdul Haseeb
Department of Medicine, Jinnah Sindh Medical University, Karachi, Pakistan
1 shared publication - Abdullah Mussarat
Department of Surgery, Jinnah Sindh Medical University, Karachi, Pakistan
1 shared publication Abyaz Asmar
Department of Neurology, Houston Methodist Hospital, Houston, TX, USA
1 shared publication- Afia Fatima
Jinnah Sindh Medical University, Karachi, Pakistan
1 shared publication - Afia Mbbs Fatima
Department of Medicine, Jinnah Sindh Medical University, Karachi, Pakistan
1 shared publication - Akhil Kumar
United Medical and Dental College, Karachi, Pakistan
1 shared publication
Latest Publications
- 22 July 2025
- Published by Wolters Kluwer Health in Cardiology in Review
Impact of Continuous Positive Airway Pressure on Cardiovascular Health in Patients With Obstructive Sleep Apnea: A Systematic Review and Meta-Analysis
Obstructive sleep apnea (OSA) is a growing health concern affecting nearly 1 billion people worldwide. Untreated OSA heightens the risk of cardiovascular (CV) complications. This meta-analysis aims to evaluate the effectiveness of continuous positive airway pressure (CPAP) in preventing adverse CV outcomes as compared with placebo or standard care in OSA patient Google Scholar, PubMed and Scopus databases were systematically searched from inception until March 2023. The outcomes of interest were major adverse CV events (MACE), all-cause mortality, CV mortality, stroke, unstable angina, new-onset atrial fibrillation (AF), myocardial infarction (MI), and hospitalization for heart failure (HF). A total of 9 361 participants from 9 randomized controlled trials and 6 observational studies were included in the analysis. Our meta-analysis reports that CPAP significantly reduces the risk of MACE [risk ratio (RR) = 0.69, 95% confidence interval (CI): 0.54–0.89] and CV mortality (RR = 0.53, 95% CI: 0.30–0.91) as compared with placebo or standard care in OSA patients. However, CPAP therapy did not show significant effects on specific CV conditions; unstable angina (RR = 1.20, 95% CI: 0.67–2.15), acute MI (RR = 0.95, 95% CI: 0.73–1.24), new-onset AF (RR = 0.89, 95% CI: 0.50–1.58), hospitalization for HF (RR = 0.83, 95% CI: 0.60–1.15), and stroke (RR = 0.89, 95% CI: 0.70–1.14). CPAP therapy significantly improves the MACE and CV mortality as compared with placebo or standard care in patients with OSA. However, no significant association was seen between CPAP and other CV outcomes, including unstable angina, MI, AF, HF hospitalization, and stroke.
- 22 July 2025
- Published by Wolters Kluwer Health in Cardiology in Review
Impact of Continuous Positive Airway Pressure on Cardiovascular Health in Patients With Obstructive Sleep Apnea: A Systematic Review and Meta-Analysis
Obstructive sleep apnea (OSA) is a growing health concern affecting nearly 1 billion people worldwide. Untreated OSA heightens the risk of cardiovascular (CV) complications. This meta-analysis aims to evaluate the effectiveness of continuous positive airway pressure (CPAP) in preventing adverse CV outcomes as compared with placebo or standard care in OSA patient Google Scholar, PubMed and Scopus databases were systematically searched from inception until March 2023. The outcomes of interest were major adverse CV events (MACE), all-cause mortality, CV mortality, stroke, unstable angina, new-onset atrial fibrillation (AF), myocardial infarction (MI), and hospitalization for heart failure (HF). A total of 9 361 participants from 9 randomized controlled trials and 6 observational studies were included in the analysis. Our meta-analysis reports that CPAP significantly reduces the risk of MACE [risk ratio (RR) = 0.69, 95% confidence interval (CI): 0.54–0.89] and CV mortality (RR = 0.53, 95% CI: 0.30–0.91) as compared with placebo or standard care in OSA patients. However, CPAP therapy did not show significant effects on specific CV conditions; unstable angina (RR = 1.20, 95% CI: 0.67–2.15), acute MI (RR = 0.95, 95% CI: 0.73–1.24), new-onset AF (RR = 0.89, 95% CI: 0.50–1.58), hospitalization for HF (RR = 0.83, 95% CI: 0.60–1.15), and stroke (RR = 0.89, 95% CI: 0.70–1.14). CPAP therapy significantly improves the MACE and CV mortality as compared with placebo or standard care in patients with OSA. However, no significant association was seen between CPAP and other CV outcomes, including unstable angina, MI, AF, HF hospitalization, and stroke.
- 11 September 2024
- Published by Elsevier in Clinical Neurology and Neurosurgery
- Vol. 246, 108523
Assessing mortality and safety of IV thrombolysis in ischemic stroke patients on direct oral anticoagulants (DOACs): A systematic review and meta-analysis
- 11 September 2024
- Published by Elsevier in Clinical Neurology and Neurosurgery
- Vol. 246, 108523
Assessing mortality and safety of IV thrombolysis in ischemic stroke patients on direct oral anticoagulants (DOACs): A systematic review and meta-analysis
- Open Access
- 6 September 2024
- Published by Wolters Kluwer Health in Medicine
- Vol. 103 (36) , e39488
Hypoglycemia and hyperglycemia in neonatal encephalopathy: A narrative review
Neonatal encephalopathy (NE) is a serious condition with various neurological dysfunctions in newborns. Disruptions in glucose metabolism, including both hypoglycemia and hyperglycemia, are common in NE and can significantly impact outcomes. Hypoglycemia, defined as blood glucose below 45 mg/dL, is associated with increased mortality, neurodevelopmental disabilities, and brain lesions on MRI. Conversely, hyperglycemia, above 120 to 150 mg/dL, has also been linked to heightened mortality, hearing impairment, and multiorgan dysfunction. Both aberrant glucose states appear to worsen prognosis compared to normoglycemic infants. Therapeutic hypothermia is the standard of care for NE that provides neuroprotection by reducing metabolic demands and inflammation. Adjunct therapies like glucagon and continuous glucose monitoring show promise in managing dysglycemia and improving outcomes. Glucagon can enhance cerebral blood flow and glucose supply, while continuous glucose monitoring enables real-time monitoring and personalized interventions. Maintaining balanced blood sugar levels is critical in managing NE. Early detection and intervention of dysglycemia are crucial to improve outcomes in neonates with encephalopathy. Further research is needed to optimize glycemic management strategies and explore the potential benefits of interventions like glucagon therapy.
- 6 September 2024
- Published by Wolters Kluwer Health in Medicine
- Vol. 103 (36) , e39488
Open AccessHypoglycemia and hyperglycemia in neonatal encephalopathy: A narrative review
Neonatal encephalopathy (NE) is a serious condition with various neurological dysfunctions in newborns. Disruptions in glucose metabolism, including both hypoglycemia and hyperglycemia, are common in NE and can significantly impact outcomes. Hypoglycemia, defined as blood glucose below 45 mg/dL, is associated with increased mortality, neurodevelopmental disabilities, and brain lesions on MRI. Conversely, hyperglycemia, above 120 to 150 mg/dL, has also been linked to heightened mortality, hearing impairment, and multiorgan dysfunction. Both aberrant glucose states appear to worsen prognosis compared to normoglycemic infants. Therapeutic hypothermia is the standard of care for NE that provides neuroprotection by reducing metabolic demands and inflammation. Adjunct therapies like glucagon and continuous glucose monitoring show promise in managing dysglycemia and improving outcomes. Glucagon can enhance cerebral blood flow and glucose supply, while continuous glucose monitoring enables real-time monitoring and personalized interventions. Maintaining balanced blood sugar levels is critical in managing NE. Early detection and intervention of dysglycemia are crucial to improve outcomes in neonates with encephalopathy. Further research is needed to optimize glycemic management strategies and explore the potential benefits of interventions like glucagon therapy.
- Top Cited PapersOpen Access
- 9 August 2024
- Published by Wolters Kluwer Health in Medicine
- Vol. 103 (32) , e39250
ChatGPT in medicine: A cross-disciplinary systematic review of ChatGPT’s (artificial intelligence) role in research, clinical practice, education, and patient interaction
Background: ChatGPT, a powerful AI language model, has gained increasing prominence in medicine, offering potential applications in healthcare, clinical decision support, patient communication, and medical research. This systematic review aims to comprehensively assess the applications of ChatGPT in healthcare education, research, writing, patient communication, and practice while also delineating potential limitations and areas for improvement. Method: Our comprehensive database search retrieved relevant papers from PubMed, Medline and Scopus. After the screening process, 83 studies met the inclusion criteria. This review includes original studies comprising case reports, analytical studies, and editorials with original findings. Result: ChatGPT is useful for scientific research and academic writing, and assists with grammar, clarity, and coherence. This helps non-English speakers and improves accessibility by breaking down linguistic barriers. However, its limitations include probable inaccuracy and ethical issues, such as bias and plagiarism. ChatGPT streamlines workflows and offers diagnostic and educational potential in healthcare but exhibits biases and lacks emotional sensitivity. It is useful in inpatient communication, but requires up-to-date data and faces concerns about the accuracy of information and hallucinatory responses. Conclusion: Given the potential for ChatGPT to transform healthcare education, research, and practice, it is essential to approach its adoption in these areas with caution due to its inherent limitations.
- 9 August 2024
- Published by Wolters Kluwer Health in Medicine
- Vol. 103 (32) , e39250
Top Cited PapersOpen AccessChatGPT in medicine: A cross-disciplinary systematic review of ChatGPT’s (artificial intelligence) role in research, clinical practice, education, and patient interaction
Background: ChatGPT, a powerful AI language model, has gained increasing prominence in medicine, offering potential applications in healthcare, clinical decision support, patient communication, and medical research. This systematic review aims to comprehensively assess the applications of ChatGPT in healthcare education, research, writing, patient communication, and practice while also delineating potential limitations and areas for improvement. Method: Our comprehensive database search retrieved relevant papers from PubMed, Medline and Scopus. After the screening process, 83 studies met the inclusion criteria. This review includes original studies comprising case reports, analytical studies, and editorials with original findings. Result: ChatGPT is useful for scientific research and academic writing, and assists with grammar, clarity, and coherence. This helps non-English speakers and improves accessibility by breaking down linguistic barriers. However, its limitations include probable inaccuracy and ethical issues, such as bias and plagiarism. ChatGPT streamlines workflows and offers diagnostic and educational potential in healthcare but exhibits biases and lacks emotional sensitivity. It is useful in inpatient communication, but requires up-to-date data and faces concerns about the accuracy of information and hallucinatory responses. Conclusion: Given the potential for ChatGPT to transform healthcare education, research, and practice, it is essential to approach its adoption in these areas with caution due to its inherent limitations.
- 20 February 2024
- Published by Springer Nature in AI and Ethics
- Vol. 5 (2) , 767-773
Prospectives and drawbacks of ChatGPT in healthcare and clinical medicine
- 20 February 2024
- Published by Springer Nature in AI and Ethics
- Vol. 5 (2) , 767-773
Prospectives and drawbacks of ChatGPT in healthcare and clinical medicine